Triaryl pyrazoline compound inhibits flavivirus RNA replication

Francesc Puig-Basagoiti, Mark Tilgner, Brett M. Forshey, Sean M. Philpott, Noel G. Espina, David E. Wentworth, Scott J. Goebel, Paul S. Masters, Barry Falgout, Ping Ren, David M. Ferguson, Pei-Yong Shi

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Triaryl pyrazoline {[5-(4-chloro-phenyl)-3-thiophen-2-yl-4,5-dihydro- pyrazol-1-yl]-phenyl-inethanone} inhibits flavivirus infection in cell culture. The inhibitor was identified through high-throughput screening of a compound library using a luciferase-expressing West Nile (WN) virus infection assay. The compound inhibited an epidemic strain of WN virus without detectable cytotoxicity (a 50% effective concentration of 28 μM and a compound concentration of ≥300 μM required to reduce 50% cell viability). Besides WN virus, the compound also inhibited other flaviviruses (dengue, yellow fever, and St. Louis encephalitis viruses), an alphavirus (Western equine encephalitis virus), a coronavirus (mouse hepatitis virus), and a rhabdovirus (vesicular stomatitis virus). However, the compound did not suppress an orthomyxovirus (influenza virus) or a retrovirus (human immunodeficiency virus type 1). Mode-of-action analyses in WN virus showed that the compound did not inhibit viral entry or virion assembly but specifically suppressed viral RNA synthesis. To examine the mechanism of inhibition of dengue virus, we developed two replicon systems for dengue type 1 virus: (i) a stable cell line that harbored replicons containing a luciferase reporter and a neomycin phosphotransferase selection marker and (ii) a luciferase-expressing replicon that could differentiate between viral translation and RNA replication. Analyses of the compound in the dengue type 1 virus replicon systems showed that it weakly suppressed viral translation but significantly inhibited viral RNA synthesis. Overall, the results demonstrate that triaryl pyrazoline exerts a broad spectrum of antiflavivirus activity through potent inhibition of viral RNA replication. This novel inhibitor could be developed for potential treatment of flavivirus infection.

Original languageEnglish (US)
Pages (from-to)1320-1329
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume50
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Flavivirus
West Nile virus
Replicon
Viral RNA
Dengue Virus
Flavivirus Infections
Luciferases
RNA
Orthomyxoviridae
St. Louis Encephalitis Viruses
Western Equine Encephalitis Viruses
Rhabdoviridae
Kanamycin Kinase
Murine hepatitis virus
Alphavirus
Yellow Fever
Coronavirus
Vesicular Stomatitis
Dengue
Virus Diseases

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Puig-Basagoiti, F., Tilgner, M., Forshey, B. M., Philpott, S. M., Espina, N. G., Wentworth, D. E., ... Shi, P-Y. (2006). Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrobial Agents and Chemotherapy, 50(4), 1320-1329. https://doi.org/10.1128/AAC.50.4.1320-1329.2006

Triaryl pyrazoline compound inhibits flavivirus RNA replication. / Puig-Basagoiti, Francesc; Tilgner, Mark; Forshey, Brett M.; Philpott, Sean M.; Espina, Noel G.; Wentworth, David E.; Goebel, Scott J.; Masters, Paul S.; Falgout, Barry; Ren, Ping; Ferguson, David M.; Shi, Pei-Yong.

In: Antimicrobial Agents and Chemotherapy, Vol. 50, No. 4, 04.2006, p. 1320-1329.

Research output: Contribution to journalArticle

Puig-Basagoiti, F, Tilgner, M, Forshey, BM, Philpott, SM, Espina, NG, Wentworth, DE, Goebel, SJ, Masters, PS, Falgout, B, Ren, P, Ferguson, DM & Shi, P-Y 2006, 'Triaryl pyrazoline compound inhibits flavivirus RNA replication', Antimicrobial Agents and Chemotherapy, vol. 50, no. 4, pp. 1320-1329. https://doi.org/10.1128/AAC.50.4.1320-1329.2006
Puig-Basagoiti F, Tilgner M, Forshey BM, Philpott SM, Espina NG, Wentworth DE et al. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrobial Agents and Chemotherapy. 2006 Apr;50(4):1320-1329. https://doi.org/10.1128/AAC.50.4.1320-1329.2006
Puig-Basagoiti, Francesc ; Tilgner, Mark ; Forshey, Brett M. ; Philpott, Sean M. ; Espina, Noel G. ; Wentworth, David E. ; Goebel, Scott J. ; Masters, Paul S. ; Falgout, Barry ; Ren, Ping ; Ferguson, David M. ; Shi, Pei-Yong. / Triaryl pyrazoline compound inhibits flavivirus RNA replication. In: Antimicrobial Agents and Chemotherapy. 2006 ; Vol. 50, No. 4. pp. 1320-1329.
@article{93267ee02a0e4d09860d5eaa28cfc026,
title = "Triaryl pyrazoline compound inhibits flavivirus RNA replication",
abstract = "Triaryl pyrazoline {[5-(4-chloro-phenyl)-3-thiophen-2-yl-4,5-dihydro- pyrazol-1-yl]-phenyl-inethanone} inhibits flavivirus infection in cell culture. The inhibitor was identified through high-throughput screening of a compound library using a luciferase-expressing West Nile (WN) virus infection assay. The compound inhibited an epidemic strain of WN virus without detectable cytotoxicity (a 50{\%} effective concentration of 28 μM and a compound concentration of ≥300 μM required to reduce 50{\%} cell viability). Besides WN virus, the compound also inhibited other flaviviruses (dengue, yellow fever, and St. Louis encephalitis viruses), an alphavirus (Western equine encephalitis virus), a coronavirus (mouse hepatitis virus), and a rhabdovirus (vesicular stomatitis virus). However, the compound did not suppress an orthomyxovirus (influenza virus) or a retrovirus (human immunodeficiency virus type 1). Mode-of-action analyses in WN virus showed that the compound did not inhibit viral entry or virion assembly but specifically suppressed viral RNA synthesis. To examine the mechanism of inhibition of dengue virus, we developed two replicon systems for dengue type 1 virus: (i) a stable cell line that harbored replicons containing a luciferase reporter and a neomycin phosphotransferase selection marker and (ii) a luciferase-expressing replicon that could differentiate between viral translation and RNA replication. Analyses of the compound in the dengue type 1 virus replicon systems showed that it weakly suppressed viral translation but significantly inhibited viral RNA synthesis. Overall, the results demonstrate that triaryl pyrazoline exerts a broad spectrum of antiflavivirus activity through potent inhibition of viral RNA replication. This novel inhibitor could be developed for potential treatment of flavivirus infection.",
author = "Francesc Puig-Basagoiti and Mark Tilgner and Forshey, {Brett M.} and Philpott, {Sean M.} and Espina, {Noel G.} and Wentworth, {David E.} and Goebel, {Scott J.} and Masters, {Paul S.} and Barry Falgout and Ping Ren and Ferguson, {David M.} and Pei-Yong Shi",
year = "2006",
month = "4",
doi = "10.1128/AAC.50.4.1320-1329.2006",
language = "English (US)",
volume = "50",
pages = "1320--1329",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Triaryl pyrazoline compound inhibits flavivirus RNA replication

AU - Puig-Basagoiti, Francesc

AU - Tilgner, Mark

AU - Forshey, Brett M.

AU - Philpott, Sean M.

AU - Espina, Noel G.

AU - Wentworth, David E.

AU - Goebel, Scott J.

AU - Masters, Paul S.

AU - Falgout, Barry

AU - Ren, Ping

AU - Ferguson, David M.

AU - Shi, Pei-Yong

PY - 2006/4

Y1 - 2006/4

N2 - Triaryl pyrazoline {[5-(4-chloro-phenyl)-3-thiophen-2-yl-4,5-dihydro- pyrazol-1-yl]-phenyl-inethanone} inhibits flavivirus infection in cell culture. The inhibitor was identified through high-throughput screening of a compound library using a luciferase-expressing West Nile (WN) virus infection assay. The compound inhibited an epidemic strain of WN virus without detectable cytotoxicity (a 50% effective concentration of 28 μM and a compound concentration of ≥300 μM required to reduce 50% cell viability). Besides WN virus, the compound also inhibited other flaviviruses (dengue, yellow fever, and St. Louis encephalitis viruses), an alphavirus (Western equine encephalitis virus), a coronavirus (mouse hepatitis virus), and a rhabdovirus (vesicular stomatitis virus). However, the compound did not suppress an orthomyxovirus (influenza virus) or a retrovirus (human immunodeficiency virus type 1). Mode-of-action analyses in WN virus showed that the compound did not inhibit viral entry or virion assembly but specifically suppressed viral RNA synthesis. To examine the mechanism of inhibition of dengue virus, we developed two replicon systems for dengue type 1 virus: (i) a stable cell line that harbored replicons containing a luciferase reporter and a neomycin phosphotransferase selection marker and (ii) a luciferase-expressing replicon that could differentiate between viral translation and RNA replication. Analyses of the compound in the dengue type 1 virus replicon systems showed that it weakly suppressed viral translation but significantly inhibited viral RNA synthesis. Overall, the results demonstrate that triaryl pyrazoline exerts a broad spectrum of antiflavivirus activity through potent inhibition of viral RNA replication. This novel inhibitor could be developed for potential treatment of flavivirus infection.

AB - Triaryl pyrazoline {[5-(4-chloro-phenyl)-3-thiophen-2-yl-4,5-dihydro- pyrazol-1-yl]-phenyl-inethanone} inhibits flavivirus infection in cell culture. The inhibitor was identified through high-throughput screening of a compound library using a luciferase-expressing West Nile (WN) virus infection assay. The compound inhibited an epidemic strain of WN virus without detectable cytotoxicity (a 50% effective concentration of 28 μM and a compound concentration of ≥300 μM required to reduce 50% cell viability). Besides WN virus, the compound also inhibited other flaviviruses (dengue, yellow fever, and St. Louis encephalitis viruses), an alphavirus (Western equine encephalitis virus), a coronavirus (mouse hepatitis virus), and a rhabdovirus (vesicular stomatitis virus). However, the compound did not suppress an orthomyxovirus (influenza virus) or a retrovirus (human immunodeficiency virus type 1). Mode-of-action analyses in WN virus showed that the compound did not inhibit viral entry or virion assembly but specifically suppressed viral RNA synthesis. To examine the mechanism of inhibition of dengue virus, we developed two replicon systems for dengue type 1 virus: (i) a stable cell line that harbored replicons containing a luciferase reporter and a neomycin phosphotransferase selection marker and (ii) a luciferase-expressing replicon that could differentiate between viral translation and RNA replication. Analyses of the compound in the dengue type 1 virus replicon systems showed that it weakly suppressed viral translation but significantly inhibited viral RNA synthesis. Overall, the results demonstrate that triaryl pyrazoline exerts a broad spectrum of antiflavivirus activity through potent inhibition of viral RNA replication. This novel inhibitor could be developed for potential treatment of flavivirus infection.

UR - http://www.scopus.com/inward/record.url?scp=33645783973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645783973&partnerID=8YFLogxK

U2 - 10.1128/AAC.50.4.1320-1329.2006

DO - 10.1128/AAC.50.4.1320-1329.2006

M3 - Article

VL - 50

SP - 1320

EP - 1329

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -